Oncotarget

Research Papers:

Hsp-27 levels and thrombus burden relate to clinical outcomes in patients with ST-segment elevation myocardial infarction

Maozhou Tian, Lingmin Zhu, Hongyang Lin, Qiaoyan Lin, Peng Huang, Xiao Yu _ and Yanyan Jing

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:73733-73744. https://doi.org/10.18632/oncotarget.17852

Metrics: PDF 873 views  |   HTML 1533 views  |   ?  


Abstract

Maozhou Tian1,*, Lingmin Zhu2,*, Hongyang Lin3,*, Qiaoyan Lin2,*, Peng Huang2,*, Xiao Yu4 and Yanyan Jing2

1Department of Cardiac Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shangdong 264000, P.R. China

2Department of Cardiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shangdong 264000, P.R. China

3Emergency Centre, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shangdong 264000, P.R. China

4Department of Endocrinology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shangdong 264000, P.R. China

*These authors are contributed equally to this work

Correspondence to:

Xiao Yu, email: yuxiaoshandong@sina.com

Yanyan Jing, email: jingyanyansd@sina.com

Keywords: Hsp-27, thrombus burden, STEMI, major adverse cardiovascular event

Received: December 06, 2016     Accepted: April 26, 2017     Published: May 13, 2017

ABSTRACT

High thrombus burden, subsequent distal embolization, and myocardial no-reflow remain a large obstacle that may negate the benefits of urgent coronary revascularization in patients with ST-segment elevation myocardial infarction (STEMI). However, the biological function and clinical association of Hsp-27 with thrombus burden and clinical outcomes in patients with STEMI is not clear. Consecutive patients (n = 146) having STEMI undergoing primary percutaneous coronary intervention (pPCI) within 12 hours from the onset of symptoms were enrolled in this prospective study in the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shangdong, P.R. China. Patients were divided into low thrombus burden and high thrombus burden groups. The present study demonstrated that patients with high-thrombus burden had higher plasma Hsp-27 levels ([32.0 ± 8.6 vs. 58.0 ± 12.3] ng/mL, P < 0.001). The median value of Hsp-27 levels in all patients with STEMI was 45 ng/mL. Using the receiver operating characteristic (ROC) curve analysis, plasma Hsp-27 levels were of significant diagnostic value for high thrombus burden (AUC, 0.847; 95% CI, 0.775–0.918; P < 0.01). The multivariate cox regression analysis demonstrated that Hsp-27 > 45 ng/mL (HR 2.801, 95% CI 1.296–4.789, P = 0.001), were positively correlated with the incidence of major adverse cardiovascular events (MACE). Kaplan-Meier survival analysis demonstrated that MACE-free survival at 180-day follow-up was significantly lower in patients with Hsp-27 > 45 ng/mL (log rank = 10.28, P < 0.001).

Our data demonstrate that plasma Hsp-27 was positively correlated with high thrombus burden and the incidence of MACE in patients with STEMI who underwent pPCI.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17852